Skip to main content
    G

    Globus Medical (GMED)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $70.02
    -0.48 (-0.68%)

    Market Cap: $9.34B

    Last updated: Nov 17, 2026 at 5:25 PM ET

    Globus Medical (GMED) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Globus Medical (GMED) has a market cap of $9.34B and an enterprise value of $8.90B. Its trailing P/E of 14.1x is below its 10-year median of 27.7x.

    Total Valuation

    Enterprise value is 4.72% below the market cap, as cash exceeds debt.

    Market Cap$9.34B
    Enterprise Value$8.90B
    Latest price (Nov 17, 2026)$70.02

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.67% in the quarter ended Sep 30, 2026 and shrank 0.54% a year over 2 years.

    Shares Outstanding134.15M
    Shares Change (YoY)-0.26%
    Shares Change (QoQ)-0.67%
    Share Count Growth (2Y CAGR)-0.54%

    Valuation Ratios

    Sales and book value multiples are 3.0x and 2.0x. Its year-end P/E ranged from 20.8x to 45.6x from 2016 to 2025.

    P/E Ratio14.1x
    Forward P/E13.8x
    P/S Ratio3.0x
    Forward P/S3.0x
    P/B Ratio2.0x
    P/TBV Ratio3.5x
    P/FCF Ratio12.3x
    P/OCF Ratio10.1x
    PEG Ratio1.0

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 9.3x EBITDA and 11.7x free cash flow.

    EV / Earnings16.0x
    EV / Sales2.8x
    EV / EBITDA9.3x
    EV / FCF11.7x

    Price Statistics

    The stock is down 17.09% over 52 weeks and trades 8.23% below its 50-day average.

    Beta (1Y)0.91
    52-Week Change-17.09%
    1-Month Change-7.44%
    3-Month Change-20.74%
    6-Month Change-12.40%
    5-Year Change+1.14%
    10-Year Change+252.69%
    Total Return (1Y)-17.09%
    Total Return (3Y CAGR)+15.39%
    Total Return (5Y CAGR)+0.26%
    Return vs SPY (1Y)-27.62%
    Max Drawdown (1Y)-27.68%
    Max Drawdown (3Y)-44.40%
    Sharpe Ratio (1Y)-0.45
    Correlation with SPY (1Y)0.32
    50-Day Average$76.30
    200-Day Average$82.50
    52-Week Range$70.14 to $101.40
    RSI (14 Days)39.0
    Average Volume (20 Days)1.99M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.30x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.30x
    Quick Ratio2.67x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 11.63% over the last 12 months, against a 5-year average of 7.23%.

    Return on Equity (ROE)11.63%
    Return on Assets (ROA)10.09%
    ROE (5Y Average)7.23%
    ROA (5Y Average)6.26%
    ROIC (5Y Average)7.03%
    Asset Turnover0.59x
    Inventory Turnover1.19x
    Receivables Turnover4.59x
    Cash Conversion Cycle347 days

    Taxes

    Income tax took 20.27% of pretax income over the last 12 months.

    Income Tax (TTM)$141.76M
    Effective Tax Rate20.27%

    Scores

    GMED has an Altman Z-Score of 9.42, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score9.42
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue of $3.14B over the last 12 months is up 13.35% from the 12 months before.

    Revenue$3.14B
    Revenue Growth (YoY)+13.35%
    Gross Profit$2.17B
    Operating Income$679.71M
    Pretax Income$699.39M
    Net Income$557.64M
    EBITDA$960.86M
    Reported EPS (TTM)$4.97

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 86.80% of the $5.53B in total assets.

    Cash and Equivalents$441.27M
    Total Debt$0
    Net Cash$441.27M
    Net Cash Per Share$3.29
    Working Capital$1.67B
    Shareholder Equity$4.80B
    Book Value Per Share$35.75
    Tangible Book Value$2.68B
    Tangible Book Per Share$19.94
    Total Assets$5.53B
    Total Liabilities$731.94M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $159.37M of capital spending, operating cash flow left $766.55M of free cash flow.

    Operating Cash Flow$925.92M
    Capital Expenditures$159.37M
    Free Cash Flow$766.55M
    FCF Per Share$6.85
    Depreciation and Amortization$285.70M
    Share Repurchases$324.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 21.65%, against a 5-year average of 14.33%.

    Gross Margin69.12%
    Operating Margin21.65%
    Pretax Margin22.28%
    Net Margin17.76%
    EBITDA Margin30.60%
    FCF Margin24.42%
    Gross Margin (5Y Average)68.12%
    Operating Margin (5Y Average)14.33%
    Net Margin (5Y Average)12.88%

    Growth

    Revenue grew 42.17% a year over 3 years, and EPS 24.56% a year.

    Revenue Growth (3Y CAGR)+42.17%
    Revenue Growth (5Y CAGR)+30.08%
    EPS Growth (3Y CAGR)+24.56%
    EPS Growth (5Y CAGR)+22.84%
    FCF Growth (3Y CAGR)+77.99%
    FCF Growth (5Y CAGR)+34.23%
    Operating Income Growth (3Y CAGR)+28.16%
    Book Value Per Share Growth (2Y CAGR)+7.65%
    Tangible Book Per Share Growth (2Y CAGR)+21.63%

    Revenue and profit by year

    Dividends and Yields

    GMED does not pay a dividend. Its free cash flow yield is 8.16%.

    Earnings Yield7.09%
    FCF Yield8.16%
    Buyback Yield3.45%
    Shareholder Yield3.45%

    Peer Position

    Against 9 similar companies, GMED has the 9th highest P/E.

    P/E Ratio14.1x vs 23.8x median
    P/S Ratio3.0x vs 3.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.35% vs +5.55% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 5.65% and EPS growth at 15.51% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+5.65%
    EPS Growth Forecast (2Y CAGR)+15.51%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GMED

    What is GMED's market cap?

    Globus Medical has a market cap of $9.34B. Its enterprise value, which adds debt and subtracts cash, is $8.90B.

    What is GMED's P/E ratio?

    Globus Medical has a trailing P/E ratio of 14.1x and a forward P/E of 13.8x.

    How many shares of GMED are outstanding?

    Globus Medical has 134.15M shares outstanding. The count is down 0.26% from a year earlier.

    Does GMED pay a dividend?

    No. Globus Medical does not pay a dividend.

    How much debt does GMED have?

    Globus Medical has $0 of total debt and $441.27M of cash and equivalents, a net cash position of $441.27M.